Medicine price rise – Truth behind the hoax
Prices of medicines have not been raised, say Pharmacists. File photo PTI
India’s drug price regulator scrapped a May guideline giving itself sweeping powers to set the price of non-essential medicines. This was a report by Live Mint on September 23. The report went on to say that –
NPPA’s July order to cap prices of new diabetes and heart disease drugs had invited strong protests and legal challenges from the drug industry…. The key drugs which were brought under control include diabetes therapies Gliclazide, Glimepiride, Sitagliptin and Voglibose; high blood pressure medications Amlodipine and Telmisartan and cholestrol treatment Rosuvastatin. The withdrawal of the guideline is on a prospective basis, so the NPPA cannot enforce similar price caps in future. But the already revised order may remain.
On October 1, a DNA report Cancer drug prices go up from Rs 8000 to 1.08 lakh said –
The Union Government(’s) decision to decontrol prices of 108 drugs — used to treat tuberculosis, AIDS, diabetes and heart ailments — has jacked up their prices. In some cases, prices have seen an unbelievable rise. The price of Glivec, an anti-cancer tablet, for example, has risen from Rs 8,500 to Rs 1.08 lakh. Plavix, used to treat blood pressure and heart ailments, will cost Rs 1,615, against the earlier Rs 147. An anti-rabi injection, Kamrab, priced at Rs 2,670, will now cost Rs 7,000. In a circular issued before Prime Minister Narendra Modi’s visit to the US, the government asked the National Pharmaceutical Pricing Authority (NPPA), an autonomous body, to withdraw its May 2014 guidelines on drug price control.
It even gives a tabulated list of medicines with earlier prices and what it claims to be the present prices. DNA is not the only one.
The ground realities are however different. A Chauthi Duniya account says that not only the prices remain as they were, there also has been no notification of possibilities of future rise of prices. The video reveals a number of media houses who have been carrying this news.
Chauthi Duniya had sent its reporters to Dharamshila Cancer Hospital, which is the second largest cancer treating hospital in Delhi and the pharmacist there said that there has been no such notification yet. In fact the present pricing and the reported pricing difference reveals it all.
Brand Name of drug (Company)
Molecule
Earlier Price as pernewspaper(Rs.)
Current Price as pernewspaper(Rs.)
Price verified by NPPA from Delhi Market
Remarks
Geftinat
(M/s Natco Pharma)
Geftinib 250mg
5,900
11,500
Rs. 5,900 for 30 tabs,
batch no. 700805, mfg dt- 08/2014, exp. dt.– 07/2016,
Non-scheduled medicine
No change in price
Glivec 400mg
(M/s Novartis)
Imatinib
8,500
1,08,000
Rs. 8452.38for 30 tabs as per Form- V dt. 10.06.2014
Scheduled medicines under DPCO, 2013,
No change in price
Cardace 5mg
(M/s Sanofi)
Ramipril
92
128
Rs.92.10 for 10 tabs
batch no. 2914016, mfg. dt.
08/2014,exp. dt 07/2017
Non-scheduled medicine,
Actually price has been brought down to Rs. 92.10 /for 10 tab on 10.07.2014 by NPPA from Rs 128 .80 in April 2014
Plavix 75 mg
(M/s Sanofi)
Clopidogrel
147
1,615
Rs. 147.44 for 14 tabs, batch no. 4A580, mfg. dt, 03/2014, exp. dt., 02/2017
Scheduled medicine
No change in price
Moxicip 400
(M/s Cipla)
Moxifloxacin
250
399
Rs.250.00 for 10 tabs, batch no. A41437, mfg dt. 07/2014, exp. dt. 06/2017
Non-scheduled medicine
No change in price
Tarivid 200
(M/s Sanofi)
Ofloxacin 200 mg
34
173
Rs. 27.20 for 5 tabs, batch no. 0214503, mfg. dt., 08/2014, exp. dt., 07/2017
Scheduled medicine
No change in price
Storvas 10 Tab
(M/s Ranbaxy)
Atorvastin 10mg
62
97
Rs.62.06 for 10 tabs, batch no. 2593309, mfg. dt- 02/2014, exp. dt- 01/2016
Scheduled medicine
No change in price
In fact these allegations are factually incorrect because the price notifications of anti-diabetic and cardio-vascular therapies issued by National Pharmaceutical Pricing Authority (NPPA) on July 10, 2014, have not been withdrawn. Till May 2014, NPPA had fixed ceiling prices of 440 scheduled drugs. Since then, ceiling prices have been fixed for additional 49 scheduled drugs. Thus the total number of scheduled drugs with fixed prices have increased from 440 to 489, ever since the Narendra Modi-led Government assumed Office. This is expected to provide financial relief to consumers by more than Rs 70 crore a year.
A September 19
Reuters report, which supports the above mentioned information, states –
India has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country’s drug pricing authority told Reuters on Friday.
Additionally, as opposed to the DNA report, the prices of 108 non-scheduled drugs for treatment of cardio vascular and diabetes were fixed by NPPA and the action taken by the body with respect to price formulations of anti- diabetic and cardio vascular therapies is expected to provide financial relief to the tune of around Rs350 crore to the consumers annually.
What is equally interesting is that Congress spokesperson Ajay Maken has written a detailed blog on this titled –
Note on How Indian Cancer/TB/AIDS and Heart Patients to bear the cost of Modi’s American Jamboree.
This is probably indicative of certain behind the curtain manipulations to malign the Narendra Modi-led Government. The way various media houses have gone about carrying this news without cross-checking the facts may not be accidental. Congress and other opposition parties jumping the fray in maligning the Government may also not be so coincidental. With Assembly Elections round the corner, it may not be wrong to believe that this was a concerted effort.
Medicine price rise – Truth behind the hoax | India News Analysis Opinions on Niti Central